Literature DB >> 26105515

KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy.

Richard Partl1, Gerd Fastner2, Julia Kaiser2, Elisabeth Kronhuber3, Klaudia Cetin-Strohmer3, Claudia Steffal4, Barbara Böhmer-Breitfelder5, Johannes Mayer5, Alexander Avian6, Andrea Berghold6.   

Abstract

PURPOSE: Low Karnofsky performance status (KPS) and elevated lactate dehydrogenases (LDHs) as a surrogate marker for tumor load and cell turnover may depict patients with a very short life expectancy. To validate this finding and compare it to other indices, namely, the recursive partitioning analysis (RPA) and diagnosis-specific graded prognostic assessment (DS-GPA), a multicenter analysis was undertaken.
METHODS: A retrospective analysis of 234 metastatic melanoma patients uniformly treated with palliative whole brain radiotherapy (WBRT) was done. Univariate and multivariate analyses were used to determine the impact of patient-, tumor-, and treatment-related parameters on overall survival (OS).
RESULTS: KPS and LDH emerged as independent factors predicting OS. By combining KPS and LDH values (KPS/LDH index), groups of patients with statistically significant differences in median OS (days; 95 % CI) after onset of WBRT were identified: group 1 (KPS ≥ 70/normal LDH) 234 (96-372), group 2 (KPS ≥ 70/elevated LDH) 112 (69-155), group 3 (KPS <70/normal LDH) 43 (12-74), and group 4 (KPS <70/elevated LDH) 29 (17-41). Between all four groups, statistically significant differences were observed. The RPA and DS-GPA indices failed to distinguish significantly between good and moderate prognosis and were inferior in predicting a very unfavorable prognosis.
CONCLUSIONS: The parameters KPS and LDH independently impacted on OS. The combination of both (KPS/LDH index) identified patients with a very short life expectancy, who might be better served by recommending best supportive care instead of WBRT. The KPS/LDH index is simple and effective in terms of time and cost as compared to other prognostic indices.

Entities:  

Keywords:  Brain metastasis; LDH; Melanoma; Prognostic score; WBRT

Mesh:

Substances:

Year:  2015        PMID: 26105515     DOI: 10.1007/s00520-015-2793-7

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  12 in total

1.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial.

Authors:  Vinai Gondi; Stephanie L Pugh; Wolfgang A Tome; Chip Caine; Ben Corn; Andrew Kanner; Howard Rowley; Vijayananda Kundapur; Albert DeNittis; Jeffrey N Greenspoon; Andre A Konski; Glenn S Bauman; Sunjay Shah; Wenyin Shi; Merideth Wendland; Lisa Kachnic; Minesh P Mehta
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

2.  Prognostic factors in patients with brain metastases from lung carcinoma.

Authors:  M Chatani; T Teshima; K Hata; T Inoue
Journal:  Strahlenther Onkol       Date:  1986-03       Impact factor: 3.621

Review 3.  Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.

Authors:  May N Tsao; Nancy Lloyd; Rebecca K S Wong; Edward Chow; Eileen Rakovitch; Normand Laperriere; Wei Xu; Arjun Sahgal
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

4.  Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.

Authors:  Thomas K Eigentler; Adina Figl; Dietmar Krex; Peter Mohr; Cornelia Mauch; Knut Rass; Azize Bostroem; Oliver Heese; Oliver Koelbl; Claus Garbe; Dirk Schadendorf
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

6.  Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma.

Authors:  Richard Partl; Erika Richtig; Alexander Avian; Andrea Berghold; Karin S Kapp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-15       Impact factor: 7.038

7.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.

Authors:  Paul W Sperduto; Samuel T Chao; Penny K Sneed; Xianghua Luo; John Suh; David Roberge; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen Shih; John Kirkpatrick; Amanda Schwer; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan Knisely; Christina Maria Sperduto; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-26       Impact factor: 7.038

8.  Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase.

Authors:  M Chatani; Y Matayoshi; N Masaki; T Inoue
Journal:  Strahlenther Onkol       Date:  1994-03       Impact factor: 3.621

9.  A survival score for patients with brain metastases from less radiosensitive tumors treated with whole-brain radiotherapy alone.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-07-18       Impact factor: 3.621

10.  Towards improved prognostic scores predicting survival in patients with brain metastases: a pilot study of serum lactate dehydrogenase levels.

Authors:  Carsten Nieder; Kirsten Marienhagen; Astrid Dalhaug; Jan Norum
Journal:  ScientificWorldJournal       Date:  2012-04-19
View more
  7 in total

1.  Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases.

Authors:  Valerio Nardone; Sara Nanni; Pierpaolo Pastina; Claudia Vinciguerra; Alfonso Cerase; Pierpaolo Correale; Cesare Guida; Antonio Giordano; Paolo Tini; Alfonso Reginelli; Salvatore Cappabianca; Luigi Pirtoli
Journal:  Strahlenther Onkol       Date:  2019-05-23       Impact factor: 3.621

2.  Examination of the predictive factors of the response to whole brain radiotherapy for brain metastases from lung cancer using MRI.

Authors:  Shuri Aoki; Tomonori Kanda; Noriyuki Matsutani; Nobuhiko Seki; Masafumi Kawamura; Shigeru Furui; Hideomi Yamashita
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

3.  Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-κB inhibition.

Authors:  Abdelouahid El-Khattouti; Denis Selimovic; Matthias Hannig; Erin B Taylor; Zakaria Y Abd Elmageed; Sofie Y Hassan; Youssef Haikel; Emad Kandil; Martin Leverkus; Robert T Brodell; Mosaad Megahed; Mohamed Hassan
Journal:  J Cell Mol Med       Date:  2015-11-18       Impact factor: 5.310

4.  Predicting prognosis of short survival time after palliative whole-brain radiotherapy.

Authors:  Kazunari Miyazawa; Naoto Shikama; Shohei Okazaki; Tadaaki Koyama; Takao Takahashi; Shingo Kato
Journal:  J Radiat Res       Date:  2018-01-01       Impact factor: 2.724

5.  Metastatic Disease to Clivus: Biopsy or Not?

Authors:  Alessandra Cathel; Yasir R Khan; Danny Blais; Bandana Mahato; Deependra Mahato
Journal:  Cureus       Date:  2019-09-14

6.  Prone position: A possible method to decrease post dural puncture headache (PDPH) during surgery.

Authors:  Reza Alizadeh; Ziba Aghsaeifard; Bahar Fereydoonnia; Masoud Hashemi; Mojtaba Mostafazadeh
Journal:  Ann Med Surg (Lond)       Date:  2022-01-25

7.  A novel inflammatory response-related signature predicts the prognosis of cutaneous melanoma and the effect of antitumor drugs.

Authors:  Jiahua Xing; Yan Li; Youbai Chen; Yan Han
Journal:  World J Surg Oncol       Date:  2022-08-19       Impact factor: 3.253

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.